(Q44754660)

English

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

scientific article published in April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

multiple sclerosis

0 references

0 references

relapsing-remitting multiple sclerosis

0 references

Per Soelberg Sørensen

5

object named as

Per Soelberg Sørensen

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Gavin Giovannoni

1

object named as

Gavin Giovannoni

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

author name string

Stuart Cook

2

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Kottil Rammohan

3

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Peter Rieckmann

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Patrick Vermersch

6

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Anthony Hamlett

7

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Vissia Viglietta

8

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Steven Greenberg

9

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

CLARITY study group

10

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

publication date

1 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

329-337

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Freedom from disease activity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Cladribine: mode of action and implications for treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of CD4 T cells in the pathogenesis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

B cells and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting short-term disability in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Short-term prognosis in early relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical outcome measures in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Will Rogers phenomenon in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Relapses and progression of disability in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Laquinimod, a new oral drug for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Measures in the first year of therapy predict the response to interferon β in MS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970023-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(11)70023-0

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44754660&oldid=2150970199"